Switching from oral antiretroviral therapy (ART) tointramuscular administration of cabotegravir-rilpivirine (CAB+RPV)eliminates the challenges related to patient adherence and compli-ance with daily oral regimens. Clinical trials have reported not onlythe virological and immunological effectiveness, but also assessedsafety and patient satisfaction. The present study evaluates, real life,the safety and effectiveness of CAB+RPV.
PLWH treated with cabotegravir-rilpivirine have increasedCD4/CD8 ratio and decreased CD8 T cells, as expressionof lower inflammation, while maintaining virologicalsuppression: a real-life 48 weeks analysis
Emmanuele Venanzi Rullo3;Giovanni Pellicanò;
2024-01-01
Abstract
Switching from oral antiretroviral therapy (ART) tointramuscular administration of cabotegravir-rilpivirine (CAB+RPV)eliminates the challenges related to patient adherence and compli-ance with daily oral regimens. Clinical trials have reported not onlythe virological and immunological effectiveness, but also assessedsafety and patient satisfaction. The present study evaluates, real life,the safety and effectiveness of CAB+RPV.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
